Rhythm(US:RYTM)2025-11-04 14:02Financial Data and Key Metrics Changes - Rhythm Pharmaceuticals reported global revenue of $51.3 million for Q3 2025, a sequential increase of 6% from $48.5 million in Q2 2025 [28] - The number of patients on reimbursed therapy increased by 10% globally during the quarter [29] - Year-over-year, net product revenues increased by $18 million, or 54%, compared to Q3 2024 [31] Business Line Data and Key Metrics Changes - Imcivree sales reached $51.3 million, driven predominantly by Bardet-Biedl Syndrome (BBS), with a 10% increase in the number of patients on reimbursed therapy [5][29] - In the U.S., $38.2 million (74% of Q3 net revenue) was generated, while $13.1 million (26% of total revenue) came from international markets [29] - The proportion of prescriptions for pediatric versus adult patients began to normalize, with 50% of new patients being adults, 22% adolescents, and 28% pediatrics [16] Market Data and Key Metrics Changes - The company has established Imcivree in over 25 countries outside the U.S. for BBS and/or POMC lipid deficiencies, with continued growth in patient numbers [22] - In France, an agreement was reached for reimbursement pricing for Imcivree, reflecting the therapeutic benefit for patients [22] - The estimated prevalence of acquired hypothalamic obesity (HO) in Europe is approximately 10,000 patients, making it a significant market opportunity [25] Company Strategy and Development Direction - The company is preparing for the launch of Imcivree in acquired hypothalamic obesity, pending FDA approval, with a PDUFA date set for December 20, 2025 [11][21] - Rhythm is focused on engaging with physicians and educating payers to secure access and support for patients long-term once treatment begins [19] - The company aims to complete enrollment of the RM-718 weekly phase II study in HO patients during Q1 2026 and initiate a phase III study with bivamelagon next year [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the upcoming launch of Imcivree for HO, highlighting the strong foundation built from the BBS launch [15][21] - The regulatory dialogue with the FDA and EMA has been productive, keeping the company on track for the upcoming approvals [6][11] - Management noted the importance of understanding the unique needs of patients and their providers as they prepare for the launch [21] Other Important Information - The company raised approximately $189 million in net proceeds from a follow-on equity offering, strengthening its balance sheet [27] - R&D expenses for Q3 were $46 million, up from $37.9 million in the same quarter last year, primarily due to increased CMC work and headcount [32] - SG&A expenses increased to $52.4 million for Q3 2025, reflecting costs associated with the upcoming launch in acquired hypothalamic obesity [32] Q&A Session Summary Question: Can you share your latest thinking on the trial design for your phase III HO study? - Management indicated that the HO trial will be a double-blind randomized controlled trial, with expectations for a full year of data [38][39] Question: Can you provide more details on the efficacy endpoints for Prader-Willi syndrome? - Management stated that success will be defined by a BMI percent change, with a focus on individual patient data rather than mean numbers [42][43] Question: What are the drivers behind the changes to the ongoing Prader-Willi trial? - Management explained that the trial was updated to allow patients to continue beyond the initial six months if they wish, and discussions about adding sites are ongoing [48][49] Question: Any updates on conversations with payers regarding the HO launch? - Management expressed optimism based on feedback from payers and indicated that they will work through the reimbursement process even if specific policies are not in place at the time of approval [52][53] Question: How should investors think about the launch curve in hypothalamic obesity? - Management highlighted the solid groundwork laid from the BBS launch and noted that while there are challenges in diagnosis, they are confident in their execution capabilities [56][58] Question: Will the initial data for Prader-Willi lead to a go/no-go decision for phase III? - Management indicated that all options are on the table, and they may decide based on the strength of the initial data [78][79] Question: How do you expect the German observational study findings to impact prescribing decisions? - Management noted that the study showed significant improvements in liver function, raising the possibility of broader implications for other indications [83][84]